StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Gyre Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -33.9%. For fiscal 2025 it was 8.5%, against 16.9% the year before. The highest annual figure on record is 16.9% in fiscal 2024.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 20258.5%−8.4
FY2024Dec 31, 202416.9%+92.3
FY2023Dec 31, 2023-75.3%−79.6
FY2022Dec 31, 20224.2%+1202.5
FY2021Dec 31, 2021-1198.3%−929.8
FY2020Dec 31, 2020-268.5%+500648.2
FY2018Dec 31, 2018-500916.7%−498798.7
FY2017Dec 31, 2017-2118.0%+286.8
FY2014Dec 31, 2014-2404.7%−2130.1
FY2013Dec 31, 2013-274.6%−262.5
FY2012Dec 31, 2012-12.1%−3.4
FY2011Dec 31, 2011-8.7%−21.5
FY2010Dec 31, 201012.7%+169.9
FY2009Dec 31, 2009-157.2%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-7.5%−13.4
Q2 FY2026Jun 30, 2026-49.0%−41.5
Q1 FY2026Mar 31, 2026-82.5%−104.9
Q4 FY2025Dec 31, 2025-5.6%−7.7
Q3 FY2025Sep 30, 20255.9%−5.3
Q2 FY2025Jun 30, 2025-7.5%−25.5
Q1 FY2025Mar 31, 202522.4%−14.2
Q4 FY2024Dec 31, 20242.1%+303.1
Q3 FY2024Sep 30, 202411.2%−12.2
Q2 FY2024Jun 30, 202418.0%+5.1
Q1 FY2024Mar 31, 202436.6%+19.6
Q4 FY2023Dec 31, 2023-300.9%+1529.8
Q3 FY2023Sep 30, 202323.4%+856.6
Q2 FY2023Jun 30, 202312.9%+1110.6
Q1 FY2023Mar 31, 202316.9%+1777.3
Q1 FY2022Mar 31, 2022-1830.7%−301.2
Q4 FY2021Dec 31, 2021-833.2%+97.8
Q3 FY2021Sep 30, 2021-1097.8%+697.6
Q2 FY2021Jun 30, 2021-1760.4%−720.1
Q1 FY2021Mar 31, 2021-1529.5%−1504.8
Q4 FY2020Dec 31, 2020-930.9%+83102.4
Q3 FY2020Sep 30, 2020-1795.4%+13.7
Q2 FY2020Jun 30, 2020-1040.3%+781.4
Q1 FY2020Mar 31, 2020-24.8%+5269.8
Q1 FY2018Mar 31, 2018-84033.3%–
Q4 FY2017Dec 31, 2017-1809.1%–
Q3 FY2017Sep 30, 2017-1821.7%–
Q2 FY2017Jun 30, 2017-5294.6%–

More Gyre Therapeutics figures

See a number that looks wrong?